APA (7th ed.) Citation

Mehta-Shah, N., Jacobsen, E., Luigi Zinzani, P., Zain, J., Mead, M., Casulo, C., . . . Horwitz, S. (2023). P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. HemaSphere, 7(S3), e3891642. https://doi.org/10.1097/01.HS9.0000971392.38916.42

Chicago Style (17th ed.) Citation

Mehta-Shah, Neha, et al. "P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY." HemaSphere 7, no. S3 (2023): e3891642. https://doi.org/10.1097/01.HS9.0000971392.38916.42.

MLA (9th ed.) Citation

Mehta-Shah, Neha, et al. "P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY." HemaSphere, vol. 7, no. S3, 2023, p. e3891642, https://doi.org/10.1097/01.HS9.0000971392.38916.42.